Safety and Efficacy of Hypoglycemic Therapy: Place of Metformin

K.A. Zuyev, Ye.N. Martsynik, D.G. Kogut


This review describes results of some basic large clinical trials on glucose lowering therapy directed on a prevention of macro- and microvascular complications of diabetes mellitus type 2. Authors emphasize that the results of these trials in relation to efficacy of modern glucose lowering therapy in terms of macrovascular complications prevention and decrease of mortality of patients with diabetes mellitus type 2 are so controversal. Taking into account the limited efficacy of glucose lowering therapy, basic question is it macrovascular safety, and also maximal removal of side effects, namely increase of risk of hypoglycemia and weight gain. From point of efficacy and safety, both in monotherapy and in the combined treatment, metformin advantageously differs from other glucose lowering preparations. The new algorithm for glucose lowering therapy based on the use of drugs that do not increase the risk of hypoglycemia and do not increase the weight has significant advantages compared to the traditional approach.


diabetes mellitus type 2; macrovascular complications of diabetes; metformin; clinical trials


Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030 // Diabetes research and clinical practice. — 2010. — 87. — P. 4-14.

Preis S.R., Hwang S.J., Coady S. et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 // Circulation. — 2009. — Vol. 119. — Р. 1728-1735.

De Boer I.H., Rue T.C., Hall Y.N. et al. Temporal trends in the prevalence of diabetic kidney disease in the United States // JAMA. — 2011 Jun 22. — 305(24). — P. 2532-2539.

Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) // Diabetes Care. — 2012. — 35(6). — Р. 1364-79.

Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes International Diabetes Federation, 2012 ( %20T2DM %20Guideline.pdf)

American Diabetes Association Standards of Medical Care in Diabetes — 2013 // Diabetes Care. — 2013. — Vol. 36. — Р. 1.

Saenz A., Fernandez-Esteban I., Mataix A. et al. Metformin monotherapy for type 2 diabetes mellitus // Cochrane Database Syst. Rev. — 2005. — 20(3). — Р. CD002966.

Nosadini R., Avogaro A., Trevisian R. et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes // Diabetes Care. — 1987. — 10. — P. 62-67.

DeFronzo R.A., Barzilai N., Simonson D.C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects // J. Clin. Endocrinol. Metab. — 1991. — 73. — 1294-1301.

Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups // Diabetes Care. — 1993. — 16. — 621-629.

Wulffelé M.G., Kooy A., de Zeeuw D. et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review // J. Intern. Med. — 2004 Jul. — 256(1). — 1-14.

Nosadini R., Avogaro A., Trevisian R. et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes // Diabetes Care. — 1987. — 10. — 62-67.

Maida A., Lamont B.J., Cao X., Drucker D.J. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice // Diabetologia. — 2011 Feb. — 54(2). — 339-49. doi: 10.1007/s00125-010-1937-z.

Evans J.M., Donnelly L.A., Emslie-Smith A.M. et al. Metformin and reduced risk of cancer in diabetic patients // BMJ. — 2005 Jun 4. — 330(7503). — 1304-5.

U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease // Diabetes. — 1995. — 44. — P. 1249-1258.

Fimognari F.L., Pastorelli R., Incalzi R.A. Phenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis) // Diabetes Care. — 2006. — 29(4). — Р. 950-1.

Daousi C., Casson I.F., Gill G.V. et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors // Postgrad. Med. J. — 2006. — 82. — Р. 280-284.

Kahn S.E., Haffner S.M., Heise M.A. et al. for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy // N. Engl. J. Med. — 2006. — Vol. 355. — P. 2427-43.

UK Perspective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweigth patients with type 2 diabetes (UKPDS 34) // Lancet. — 1998. — 352(9131). — Р. 854-865.

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — 358. — P. 2560-2572.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. — 2008. — 358. — P. 2545-2559.

Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. — 2009. — 360. — P. 129-139.

Zoungas S., Heerspink L. et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial // Oral presentation presented at EASD 2011.

Scirica B.M., Bhatt D.L., Braunwald E. et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus // N. Engl. J. Med. — 2013. — 369. — Р. 1317-26.

White W.B., Cannon C.P., Heller S.R. et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes // N. Engl. J. Med. — 2013. — 369. — P. 1327-35.

The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia // N. Engl. J. Med. — 2012. — 367. — P. 319-328.

Zoungas S., Patel A. et al. Severe Hypoglycemia and Risks of Vascular Events and Death // N. Engl. J. Med. — 2010. — 363. — P. 1410-1418.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. — 1998. — 352(9131). — P. 837-853.

Chobanian A.V., Bakris G.L., Black H.R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure // Hypertension. — 42. — Р. 1206-1252.

Grundy S.M. Obesity, Metabolic Syndrome, and Cardiovascular Disease // The Journal of Clinical Endocrinology & Metabolism. — 2004. — 89. — Р. 2595-2600.

Seidell J.C., Verschuren W.M., van Leer E.M., Kromhout D. Overweight, underweight, and mortality. A prospective study of 48,287 men and women // Arch. Intern. Med. — 1996. — 156(9). — Р. 958-63.

Bastard J.P., Antuna-Puente B., Feve B., Fellahi S. Adipokines: The missing link between insulin resistance and obesity. // Diabetes Metab. — 2008. — 34(1). — Р. 2-11.

Bosello O., Zamboni M. Visceral obesity and metabolic syndrome // Obes. Rev. — 2000. — 1. — Р. 47-56.






  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг